EUVIMEDEUVIMED entdecken
Crossref

Schisandrin C prevents regorafenib-induced cardiotoxicity by recovering EPHA2 expression in cardiomyocytes

Bo Xu, Ning Liu, Taicheng Zhou, Jian Chen, Liyu Jiang, Wentong Wu, Huangxi Fu, Xueqin Chen, Hao Yan, Xiaochun Yang, Peihua Luo iD, Bo Yang und 2 weitere

Toxicological Sciences · 2024

DOI: 10.1093/toxsci/kfae127 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Toxicological Sciences, 2024. Verfasst von Bo Xu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Center for Drug Safety Evaluation and Research of Zhejiang University, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang 31…. Hauptthemen laut MEDLINE: Myocytes, Cardiac, Receptor, EphA2, Cardiotoxicity, Phenylurea Compounds. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 60 Literaturangaben. Gefördert von: Fundamental Research Funds for the Central Universities, Natural Science Foundation of Zhejiang Province, Zhejiang Provincial Medical and Health Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Regorafenib, an oral multikinase inhibitor of angiogenic, stromal, and oncogenic receptor tyrosine kinases, has been approved for the treatment of metastatic colorectal cancer, gastrointestinal stromal tumors, and hepatocellular carcinoma by the US Food and Drug Administration and European Medicines Agency. However, regorafenib-induced cardiotoxicity increases the risk of mortality. Despite reports that regorafenib can cause mitochondrial dysfunction in cardiomyocytes, the molecular mechanism of regorafenib-induced cardiotoxicity is much less known and there is an urgent need for intervention strategies. Here, we treated mice with vehicle or 200 mg/kg regorafenib daily for 42 d by gavage or treated cardiomyocyte lines with 8, 16, or 32 μM regorafenib, and we found that regorafenib could cause apoptosis, mitochondrial injury, and DNA damage in cardiomyocytes. Mechanistically, regorafenib can reduce the expression of EPHA2, which inhibits AKT signaling, leading to cardiomyocyte apoptosis and cardiotoxicity. In addition, we showed that recovering EPHA2 expression via plasmid-induced overexpression of EPHA2 or schisandrin C, a natural product, could prevent regorafenib-induced cardiotoxicity. These findings demonstrated that regorafenib causes cardiomyocyte apoptosis and cardiac injury by reducing the expression of EPHA2 and schisandrin C could prevent regorafenib-induced cardiotoxicity by recovering EPHA2 expression, which provides a potential management strategy for regorafenib-induced cardiotoxicity and will benefit the safe application of regorafenib in clinic.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myocytes, CardiacReceptor, EphA2CardiotoxicityPhenylurea CompoundsPyridinesCyclooctanesApoptosisLignansAnimalsMicePolycyclic CompoundsMaleMice, Inbred C57BLHumansCell LineDNA DamageSignal Transduction

Stichwörter der Autor:innen

DNA damageEPHA2apoptosiscardiotoxicityregorafenibschisandrin C

Substanzen

regorafenibReceptor, EphA2Phenylurea CompoundsPyridinesCyclooctanesLignansPolycyclic Compounds

Autor:innen und Institutionen

  • Center for Drug Safety Evaluation and Research of Zhejiang University, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang 310058, P.R. China.
  • Emergency Department, Sir Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310016, P.R. China.
  • Department of Pharmacy, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310009, P.R. China.
  • Department of Medical Oncology, Affiliated Hangzhou First People's Hospital, Xihu University School of Medicine, Hangzhou, Zhejiang 310006, P.R. China.
  • Department of Cardiology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310009, P.R. China.
  • Innovation Institute for Artificial Intelligence in Medicine of Zhejiang University, Hangzhou, Zhejiang 310018, P.R. China.

ORCID-Profile: Peihua Luo

Förderung

  • Fundamental Research Funds for the Central Universities
  • Natural Science Foundation of Zhejiang Province
  • Zhejiang Provincial Medical and Health Technology

Zitieren

APA

Xu, B., Liu, N., Zhou, T., Chen, J., Jiang, L., Wu, W., Fu, H., Chen, X., Yan, H., Yang, X., Luo, P., Yang, B., Xu, Z., & He, Q. (2024). Schisandrin C prevents regorafenib-induced cardiotoxicity by recovering EPHA2 expression in cardiomyocytes. Toxicological Sciences. https://doi.org/10.1093/toxsci/kfae127

Vancouver

Xu B, Liu N, Zhou T, Chen J, Jiang L, Wu W, et al. Schisandrin C prevents regorafenib-induced cardiotoxicity by recovering EPHA2 expression in cardiomyocytes. Toxicological Sciences. 2024. doi:10.1093/toxsci/kfae127

BibTeX
@article{Xu2024,
  author = {Xu, Bo and Liu, Ning and Zhou, Taicheng and Chen, Jian and Jiang, Liyu and Wu, Wentong and Fu, Huangxi and Chen, Xueqin and Yan, Hao and Yang, Xiaochun and Luo, Peihua and Yang, Bo and Xu, Zhifei and He, Qiaojun},
  title = {Schisandrin C prevents regorafenib-induced cardiotoxicity by recovering EPHA2 expression in cardiomyocytes},
  journal = {Toxicological Sciences},
  year = {2024},
  doi = {10.1093/toxsci/kfae127}
}
Kostenlos starten →